Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancer.
Kelly R, Jensen A, Karunaratna N, Wong S, Shapiro J, Weickhardt A, Parente P, Azad AA, Uccellini A, Torres J, Parnis F, Goh J, Kwan EM, Brown S, Steer C, Warren M, Gibbs P, Tran B, Anton A. Kelly R, et al. Among authors: parnis f. BJU Int. 2023 Feb;131(2):179-182. doi: 10.1111/bju.15930. Epub 2022 Nov 30. BJU Int. 2023. PMID: 36371671 No abstract available.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Davis ID, et al. Among authors: parnis f. N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157964 Clinical Trial.
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?
Pereira-Salgado A, Anton A, Franchini F, Mahar RK, Kwan EM, Wong S, Shapiro J, Weickhardt A, Azad AA, Spain L, Gunjur A, Torres J, Parente P, Parnis F, Goh J, Steer C, Brown S, Gibbs P, Tran B, IJzerman M. Pereira-Salgado A, et al. Among authors: parnis f. Expert Rev Pharmacoecon Outcomes Res. 2023 Feb;23(2):231-239. doi: 10.1080/14737167.2023.2161048. Epub 2022 Dec 28. Expert Rev Pharmacoecon Outcomes Res. 2023. PMID: 36541133
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Sweeney CJ, et al. Among authors: parnis f. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3. Lancet Oncol. 2023. PMID: 36990608 Clinical Trial.
Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations.
Conduit C, Lewin J, Weickhardt A, Lynam J, Wong S, Grimison P, Sengupta S, Pranavan G, Parnis F, Bastick P, Campbell D, Hansen AR, Leonard M, McJannett M, Stockler MR, Gibbs P, Toner G, Davis ID, Tran B, Kuchel A. Conduit C, et al. Among authors: parnis f. JCO Oncol Pract. 2023 Nov;19(11):973-980. doi: 10.1200/OP.23.00191. Epub 2023 Jun 16. JCO Oncol Pract. 2023. PMID: 37327464
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial.
Clarke NW, Armstrong AJ, Oya M, Shore N, Procopio G, Daniel Guedes J, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Young Joung J, Sugimoto M, Sartor O, Poehlein C, McGuinness D, Degboe A, Saad F. Clarke NW, et al. Among authors: parnis f. Eur Urol Oncol. 2024 Oct 8:S2588-9311(24)00222-0. doi: 10.1016/j.euo.2024.09.013. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39384451 Free article.
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG, Postow MA, Gaudy-Marqueste C, Medina T, Lao CD, Walker J, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Sandhu S, Lebbé C, Ascierto PA, Long GV, Ritchings C, Nassar A, Askelson M, Benito MP, Wang W, Hodi FS, Larkin J; CheckMate 067 Investigators. Wolchok JD, et al. N Engl J Med. 2025 Jan 2;392(1):11-22. doi: 10.1056/NEJMoa2407417. Epub 2024 Sep 15. N Engl J Med. 2025. PMID: 39282897 Clinical Trial.
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.
Necchi A, Van der Heijden MS, Trukhin D, Peer A, Gurney H, Alekseev BY, Parnis FX, Leibowitz R, De Santis M, Grivas P, Clark J, Munteanu M, Kataria R, Jia C, Balar AV, de Wit R. Necchi A, et al. Among authors: parnis fx. BMC Cancer. 2024 Jul 25;23(Suppl 1):1252. doi: 10.1186/s12885-023-10727-3. BMC Cancer. 2024. PMID: 39054491 Free PMC article. Clinical Trial.
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.
Cicin I, Plimack ER, Gurney H, Leibowitz R, Alekseev BY, Parnis FX, Peer A, Necchi A, Bellmunt J, Nishiyama H, Clark J, Munteanu M, Kataria R, Jia C, Powles T, Sternberg CN. Cicin I, et al. Among authors: parnis fx. BMC Cancer. 2024 Jul 25;23(Suppl 1):1256. doi: 10.1186/s12885-023-11213-6. BMC Cancer. 2024. PMID: 39054485 Free PMC article. Clinical Trial.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
73 results